Soulières, Denis http://orcid.org/0000-0002-1533-3815
Mercier-Ross, Jules
Fradette, Caroline
Rozova, Anna
Tsang, Yu Chung
Tricta, Fernando
Funding for this research was provided by:
apopharma inc (now chiesi) was the sponsor of the study.
Article History
Received: 28 June 2021
Accepted: 18 November 2021
First Online: 4 January 2022
Declarations
:
: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) This study was conducted in accordance with the accepted version of the Declaration of Helsinki 1975, as revised in 2008. The study was approved by Centre Hospitalier Université de Montréal (CHUM) ethics committee.
: Informed consent was obtained from all individual participants included in the study.
: All of the authors have approved of the final submitted version.
: Denis Soulières is a participant on ApoPharma advisory board and received ApoPharma institutional grant.Jules Mercier-Ross has no conflict of interest to declare.Caroline Fradette is an employee of Chiesi Canada.Anna Rozova is an employee of Chiesi Canada.Yu Chung Tsang is an employee of Apotex Inc., which is the contract manufacturer of the drug product (i.e., FERRIPROX®) used in the study reported in this manuscript.Fernando Tricta is an employee of Chiesi Canada.